-
Investor Relations
- Corporate Governance
- Investor Presentations
- Annual Reports
- Compliance and AML
- Sustainability
- Financial Information
- Shareholders Toolkit
- FAQs
- Investors’ Queries
-
-
-
Accounts
- Al Hayrat Account
- Current Account
- Fixed Deposits Account
- Money Maker Account
- Salary Transfer Account
- Starmaker Account
- Super Saver Account
-
Al Wajaha
- Overview
-
BBK Lite
- Overview
-
NRI
- NRI Services
-
Debit Cards
- Classic
- Gold
- Signature
- Infinite
-
Self-service Banking
- ATM
- Deposit Machines
- Interactive Teller Machines
- Bank Certificates Issuance Machines
- Debit Card Issuance Machines
-
Foreign Exchange
- Remittance
- American Express
-
-
-
Insurance
- Home Secura
- Motor Secura
- Travel Secura
-
Investment
- Bonds
- IPO
- Mutual Funds
- Real Estate Investment
-
-
-
Branches and Self-Service
- Branches
- ATM
- Deposit Machines
- Debit Card Issuance Machines
- Corporate Deposit Machines
- Interactive Teller Machines
- Bank Certificates Issuance Machines
-
Contactless Payments
- Apple Pay
- Samsung Wallet
- Google Pay
- Garmin Pay
- Fitbit Pay
-
More Ways to Bank
- Mobile app & Online Banking
- eStatements
- BBK BanKey
- Corporate Deposit Card
- Debit Card
- Telebanking
- Open Banking
- AFAQ Payment System
- Remittance
- Visa Click to Pay
-
Sign Language
- Sign Language Directory
-
-
-
-
-
Accounts
- Business Current Account
- Business Fixed Deposit Account
-
Cash Management
- Bankey eBanking
- Payroll Services
- Deposit Machines
- POS Credimax
- Remittance
-
-
-
Working Capital Finance
- Overdraft
- Cheque discounting
- Short Term Loans
-
Long Term Finance
- Project Finance
- Assets Finance
- Real estate Finance
-
-
-
Corporate Banking
- Government Affairs
- Real Estate, Services and Trading
- Contracting, Building Material, and Manufacturing
-
International Banking
- Overview
- Services
- NRI
- Offshore Branches
- Representative offices
-
Enterprise Banking
- Overview
-
-
-
-
-
FINANCIAL NEWS
Jordan- Hikma Pharmaceuticals expects 2013 revenue to grow 13%
16 May 2013
(MENAFN) Hikma Pharmaceuticals Plc CEO, Said Darwazah, stated that the drugmaker expects its 2013 revenue to grow by nearly 13 percent from 2012, compared with an earlier forecast of 10 percent, reported Reuters.
Darwazah added that the increase would be driven by higher revenue of its generic antibiotic doxycycline.
Last year’s revenue stood at USD1.11 billion, of which generic business accounted for USD103.7 million and injectables for USD470 million.
Jordan’s Hikma has been taking advantage of a drug shortage in the US as a number of generic drug manufacturers have been forced to lower capacity in the face of stringent regulatory scrutiny.
In November, the firm discontinued commercial production at its Eatontown, New Jersey plant to ensure conformity with US FDA rules.
It is worth noting that Hikma, established in 1978, projected the generic business to incur one-off remediation costs and inventory write-downs of between USD25 million and USD30 million in 2013.
More News
13 Apr 2026
BBK launches the Youth Advisory Council (YAC) to empower youth and advance innovation
08 Apr 2026
BBK awards over BD 1 Million to 273 winners in the February Al Hayrat Grand Prizes draw
01 Mar 2026
BBK activates partial remote working system for its workforce to ensure employee and customer safety and service continuity
24 Feb 2026
BBK discloses its financial results for the year ended 31st December 2025
05 Feb 2026
BBK announces December Al Hayrat Grand Prize winners and another wave of Grand prizes for February
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more